<DOC>
	<DOCNO>NCT00710333</DOCNO>
	<brief_summary>This trial ass safety efficacy 500ng Juvista per linear cm wound margin administer intradermal injection follow excision keloid scar ear lobe . Ear lobe keloid commonly occur ear pierce particularly distress patient difficult conceal usually bilateral . As recurrence rate growth rate keloid vary significantly individual , trial subject bilateral ear lobe keloid act control . One ear lobe treat Juvista follow keloid excision one placebo .</brief_summary>
	<brief_title>Safety Juvista When Administered Following Excision Ear Lobe Keloids</brief_title>
	<detailed_description />
	<mesh_term>Keloid</mesh_term>
	<criteria>Patients age 1885 year give write informed consent . Patients bilateral ear lobe keloid scar suitable surgical excision result single wound ear lobe great 2cm long restricted skin , fat fibrous tissue ear lobe . Patients , opinion investigator , clinically acceptable result laboratory test specify trial protocol ( see Protocol Section 6.3.2 ) . All laboratory test must perform within 28 day first trial dose administration . Female patient child bear potential use highly effective method ( ) contraception agree least screen visit one month administration final study dose . For purpose protocol , highly effective method ( ) contraception define consistently correctly used implant , injectables , combine oral contraceptive , sexual abstinence vasectomise partner . Patients ear lobe keloid treat irradiation , cryosurgery , corticosteriods , pharmacological agent three month prior first trial dose administration . Patients history bleed disorder . Patients direct question and/or physical examination past present evidence eczema psoriasis local site administration , uncontrolled diabetes ( fast plasma glucose concentration consistently 7.0mmol 11 ( 126 mg dl1 ) , severely immunocompromised patient and/or malignant skin tumour e.g . melanoma , squamous basal cell carcinoma . Patients skin disorder , relate keloid disease , chronic currently active Investigator considers adversely affect heal acute wound involve area examine trial . Patients history malignancy last 5 year . Patients history hypersensitivity drug dressing use trial . Patients take , take investigational product participate clinical trial three month prior first trial dose administration . Patients undergoing investigation change management exist medical condition . Patients , opinion Investigator , unlikely complete trial whatever reason . Female patient pregnant lactate . Patients creatinine clearance ( CLcr ) 80ml/min less . Creatinine clearance determine serum creatinine level prestudy screen use follow formula . CLcr = ( 140age ( year ) ) x weight ( kg ) / 72 x serum creatinine ( mg/dL ) { x 0.85 female } Patients able undergo MRI scanning due medical history Physical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>